Triple
T7930645
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Calico |
E184180
|
entity |
| Predicate | fullName |
P16
|
FINISHED |
| Object | Calico Life Sciences LLC |
E35320
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Calico Life Sciences LLC | Statement: [Calico, fullName, Calico Life Sciences LLC]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Calico Life Sciences LLC Context triple: [Calico, fullName, Calico Life Sciences LLC]
-
A.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
B.
Calico LLC
chosen
Calico LLC is a research and development company focused on understanding aging and developing technologies to extend human healthspan, backed by Alphabet Inc.
-
C.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
D.
Nautilus Biotechnology
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
E.
Ridgeback Biotherapeutics
Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca8290c21c8190906a5ca6fe2b03c4 |
completed | March 30, 2026, 2:02 p.m. |
| NER | Named-entity recognition | batch_69cb3accc388819087065ebe7d5d9591 |
completed | March 31, 2026, 3:09 a.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69cb5c01602081908ea1af24785260ff |
completed | March 31, 2026, 5:30 a.m. |
Created at: March 30, 2026, 5:07 p.m.